ELZONRIS®
Publications
New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Presentations
Phase I Study of Tagraxofusp +/- Chemotherapy in Pediatric Patients with R/R CD123-Expressing Hematologic Malignancies: A TACL Consortium Trial. ASH 2022.
Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial. ASH 2022.
Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP. ASH 2022.
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF. ASH 2021.
Tagraxofusp Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease. ASH 2021.
SL-801
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2019.
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2018.
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors. ASCO 2018.
Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results. ESMO 2017.
SL-801, a novel, reversible inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with broad and potent anti-cancer activity. ASH 2015.
SL-701
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). SNO 2018
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). ESMO 2018
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival. ASCO 2018.
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM. SNO 2017.
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM: Interim results. SNO 2016.
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma. SNO 2014.